Viromed Medical AG Completes Study on Cold Plasma Application in the Lung, Shows Promise for Treating Ventilator-Associated Pneumonia
Viromed Medical AG announces successful completion of a multi-year study on cold atmospheric plasma in the lung, demonstrating potential as a non-pharmacological treatment for severe infectious lung diseases, with first successful patient applications already achieved.
Viromed Medical AG (ISIN: DE000A40ZVN7), a medical technology company specializing in cold plasma technology, announced today the successful completion of a multi-year study on the application of cold atmospheric plasma (CAP) in the lung. The study focused on ventilator-associated pneumonia (VAP), a critical challenge in intensive care medicine, and the results confirm the potential of cold plasma as a physical, non-pharmacological treatment option for severe infectious lung diseases.
The data show a clearly defined therapeutic safety window and complete reduction of pathogenic germs in lung epithelial models. The study included ex vivo validation on vital lungs in collaboration with Saarland University and Hannover Medical School, using an isolated, ventilation- and perfusion-capable lung model that reflects key physiological characteristics of the human lung.
Uwe Perbandt, Member of the Management Board of Viromed Medical AG, stated: "By successfully completing this study, we have reached a point of outstanding importance for Viromed and for modern pneumology. The data confirm the potential of our cold plasma technology in one of the most sensitive organ systems of the human body." He added that the company is now seeing first successful applications in patients in a university clinical setting, opening a new chapter in intensive care and infectious medicine.
Based on the study results, Viromed's technology has already been used in a university setting for a severe pulmonary individual case in a human patient following approval by the responsible ethics committee. A university hospital with a department specializing in lung and transplantation medicine treated a patient in connection with a lung transplant and massive complications. The use of cold plasma was very successful, and the treating physicians assessed the positive clinical course as exceptional. The hospital plans to publish the case in the near term, and further severely ill patients with a high risk of a fatal outcome are undergoing treatment.
Viromed sees clear indications that cold plasma technology will fundamentally change pneumology. While classical pharmacological therapies are increasingly limited by the development of resistance, cold plasma as a physical mode of action opens up a new therapeutic dimension, including the prevention of severe pulmonary infections. Looking ahead, further applications in intensive care medicine are moving into clinical research use, such as intracardiac use in operations for bacterial endocarditis before implantation of a valve prosthesis, or application in the thorax for bacterial pleural empyema.
For more information, visit Viromed Medical AG. The original press release is available on NewMediaWire.